Stocktoria
Krystal Biotech, Inc. KRYS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-09-20
Krystal Biotech, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 |
| R&D expense | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M |
| SG&A expense | $146.7M | $113.6M | $98.3M | $77.7M | — |
| Operating income | $161.3M | $65.7M | -$109.6M | -$145.2M | -$68.3M |
| Interest expense | — | — | $0 | $0 | $1.5M |
| Income tax | -$15.4M | $6.2M | $2.0M | $0 | $0 |
| Net income | $204.8M | $89.2M | $10.9M | -$140.0M | -$69.6M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
| Operating cash flow | $200.9M | $123.4M | -$88.8M | -$100.6M | -$47.9M |
| Free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M | -$116.3M |
| Cash & equivalents | $496.3M | $344.9M | $358.3M | $161.9M | $341.2M |
| Inventory | $40.5M | $26.5M | $7.0M | $0 | — |
| Total assets | $1.3B | $1.1B | $818.4M | $558.5M | $626.3M |
| Total liabilities | $114.2M | $109.5M | $39.7M | $36.2M | $32.7M |
| Shareholders' equity | $1.2B | $946.4M | $778.6M | $522.2M | $593.6M |
Source: SEC EDGAR filings · CIK 0001711279 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.